Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug JARDIANCE

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug JARDIANCE

Annual Drug Patent Expirations for JARDIANCE
Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

JARDIANCE drug price trends.

Drug patent litigation for JARDIANCE.

This drug has one hundred and ninety-eight patent family members in forty-four countries.

The generic ingredient in JARDIANCE is empagliflozin. Four suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug JARDIANCE
Find your next blockbuster

Get accurate and timely intelligence — in just a few clicks

✓ Free trial

✓ No credit card

 

DrugPatentWatch - Make Better Decisions